DLL3 and neoplasm: The initial human study (FIH) of Rova-T demonstrated an ORR of 18%, which notably increased to 38% among patients with high DLL3 expression in SCLC (defined as DLL3 expression in ≥ 50% of tumor cells as determined by IHC) [111].